Bank of New York Mellon’s Regulus Therapeutics RGLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-149,355
| Closed | -$261K | – | 4246 |
|
|
2025
Q1 | $261K | Hold |
149,355
| – | – | ﹤0.01% | 3766 |
|
|
2024
Q4 | $236K | Sell |
149,355
-1
| -0% | -$2 | ﹤0.01% | 3887 |
|
|
2024
Q3 | $234K | Sell |
149,356
-47,837
| -24% | -$79.1K | ﹤0.01% | 3864 |
|
|
2024
Q2 | $352K | Buy |
+197,193
| New | +$458K | ﹤0.01% | 3744 |
|
|
2019
Q1 | – | Sell |
-2,730
| Closed | -$25K | – | 4241 |
|
|
2018
Q4 | $25K | Buy |
2,730
+2,445
| +858% | +$40.5K | ﹤0.01% | 4136 |
|
|
2018
Q3 | $7K | Hold |
285
| – | – | ﹤0.01% | 4233 |
|
|
2018
Q2 | $23K | Sell |
285
-277
| -49% | -$22.9K | ﹤0.01% | 4161 |
|
|
2018
Q1 | $49K | Buy |
562
+256
| +84% | +$34.3K | ﹤0.01% | 4173 |
|
|
2017
Q4 | $39K | Buy |
306
+21
| +7% | +$2.66K | ﹤0.01% | 4233 |
|
|
2017
Q3 | $43K | Buy |
285
+81
| +40% | +$10.2K | ﹤0.01% | 4130 |
|
|
2017
Q2 | $24K | Sell |
204
-766
| -79% | -$128K | ﹤0.01% | 4215 |
|
|
2017
Q1 | $192K | Sell |
970
-140
| -13% | -$26.6K | ﹤0.01% | 3894 |
|
|
2016
Q4 | $299K | Sell |
1,110
-30
| -3% | -$9.75K | ﹤0.01% | 3784 |
|
|
2016
Q3 | $452K | Sell |
1,140
-37
| -3% | -$15.2K | ﹤0.01% | 3591 |
|
|
2016
Q2 | $408K | Buy |
1,177
+168
| +17% | +$120K | ﹤0.01% | 3621 |
|
|
2016
Q1 | $839K | Sell |
1,009
-71
| -7% | -$56.5K | ﹤0.01% | 3170 |
|
|
2015
Q4 | $1.13M | Buy |
1,080
+102
| +10% | +$102K | ﹤0.01% | 3090 |
|
|
2015
Q3 | $767K | Sell |
978
-195
| -17% | -$200K | ﹤0.01% | 3344 |
|
|
2015
Q2 | $1.54M | Buy |
1,173
+562
| +92% | +$907K | ﹤0.01% | 3078 |
|
|
2015
Q1 | $1.24M | Buy |
611
+3
| +0.5% | +$6.52K | ﹤0.01% | 3175 |
|
|
2014
Q4 | $1.17M | Buy |
608
+80
| +15% | +$142K | ﹤0.01% | 3214 |
|
|
2014
Q3 | $433K | Hold |
528
| – | – | ﹤0.01% | 3684 |
|
|
2014
Q2 | $509K | Buy |
528
+40
| +8% | +$34.3K | ﹤0.01% | 3600 |
|
|
2014
Q1 | $529K | Sell |
488
-5
| -1% | -$5.54K | ﹤0.01% | 3570 |
|
|
2013
Q4 | $437K | Buy |
493
+12
| +2% | +$10.3K | ﹤0.01% | 3626 |
|
|
2013
Q3 | $544K | Sell |
481
-1
| -0.2% | -$1.18K | ﹤0.01% | 3488 |
|
|
2013
Q2 | $568K | Buy |
+482
| New | +$458K | ﹤0.01% | 3445 |
|
Other funds holding RGLS
Bank of New York Mellon's RGLS Position: Q2 2025 in Review
Bank of New York Mellon sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 149,355 shares — an estimated $261K sold.
Bank of New York Mellon first reported a position in RGLS in Q2 2013 and held it in 27 quarters. The position peaked at $1.54M in Q2 2015. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.
- Bank of New York Mellon reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
- Bank of New York Mellon sold 149,355 Regulus Therapeutics shares in Q2 2025, an estimated $261K.
- Bank of New York Mellon first reported a position in Regulus Therapeutics in Q2 2013 and held it in 27 quarters.
- Bank of New York Mellon's Regulus Therapeutics position peaked at $1.54M in Q2 2015.
- 0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.
Based on Bank of New York Mellon's 13F filing for Q2 2025, filed 5 Aug 2025.